# Enantios

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enantios

- Industry: Pharmaceuticals
- Headquarters: Zurich, Switzerland
- Website: www.enantios.ch
- Total disclosed funding: $2M
- Latest round: Seed (Jun 27, 2024)
- Investors on record: 2

## About

Based in Zurich, Switzerland, and founded in 2022 by Chief Executive Officer Carin R. Lightner and Chief Technology Officer Roman Wyss, Enantios operates as a technology company that offers analytical instruments to provide precise and accurate measurements of chirality and molecular structure. In January 2024, Enantios raised venture funding from S2S Ventures and Zürcher Kantonalbank.

Enantios developed a benchtop instrument based on Raman Optical Activity (ROA) technology. The company’s device uses technology that allows users to nondestructively characterize a wide range of molecules and can resolve structures that are impossible to measure with existing tools. The firm also provides measurement services for characterizing chiral molecules and biologics. Its ROA technology is an optical effect that can determine the structure of complex molecules without the need for calibration on virtually any molecule.

## Funding rounds

- Seed, Jun 27, 2024, $2M — Zürcher Kantonalbank, Privilege Ventures

## Investors

- Zürcher Kantonalbank — Seed
- Privilege Ventures (https://capitalatlas.ai/funds/privilege-ventures) — Seed